CD44 and breast cancer: These predictions were supported experimentally by showing that breast cancer cells with hybrid E/M phenotypes, marked by co-expression of CD44 (mesenchymal mark) and CD24 (epithelial mark), have increased levels of cleaved Notch intercellular domain (NICD), which activates Jagged but represses Delta, compared to mesenchymal cells [15].